Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Akili, Inc.

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Reports First Quarter 2024 Financial Results and Provides Business Update
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates
From Akili, Inc.
Via Business Wire
Tickers AKLI
EndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Reports Third Quarter 2023 Financial Results and Provides Business Update
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET
From Akili, Inc.
Via Business Wire
Tickers AKLI
Employees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study Finds
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Announces Leadership Transition
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Announces Business Transformation, Focusing on Non-prescription Model
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Reports Second Quarter 2023 Financial Results and Provides Business Update
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ET
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHD
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Reports First Quarter 2023 Financial Results and Provides Business Update
From Akili, Inc.
Via Business Wire
Tickers AKLI
Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 11 at 4:30 p.m. ET
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, March 7 at 4:30 p.m. ET
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili to Participate in the Cowen 43rd Annual Health Care Conference
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili to Champion Digital Therapeutics in Conjunction with J.P. Morgan Healthcare Conference
From Akili, Inc.
Via Business Wire
Tickers AKLI
Pivotal Trial of EndeavorRxⓇ in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Announces ADHD Expert Dr. Scott Kollins to Join as Chief Medical Officer
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Reports Third Quarter 2022 Financial Results and Company Update
From Akili, Inc.
Via Business Wire
Tickers AKLI
Financial Industry Veteran Mary Hentges Joins Akili’s Board of Directors
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 10 at 4:30 p.m. ET
From Akili, Inc.
Via Business Wire
Tickers AKLI
Akili Launches EndeavorRx® Expedition - A Direct-to-Patient Product Registry
From Akili, Inc.
Via Business Wire
Tickers AKLI
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.